Calcitonin Gene–Related Peptide Reduces Brain Injury in a Rat Model of Focal Cerebral Ischemia

Jeremy P. Holland, BSc, FRCS; Simon G.C. Sydserff, BSc; William A.S. Taylor, FRCS; B. Anthony Bell, MD, FRCS

Methods

Calcitonin gene–related peptide (CGRP) is a 37–amino acid peptide with a wide distribution throughout a variety of tissues, including the nervous system, that has particularly high concentrations in the cerebral vasculature.1 α-CGRP is produced by alternative processing of the calcitonin gene product and predominates in the trigeminocerebrovascular system2–5 but differs by only three amino acids from β-CGRP, which is encoded by a separate gene6 and predominates in the periphery.2 The exact physiological role of these peptides and the reason for their differential expression remains unclear, but both are potent vascular smooth muscle relaxants, indicating a role in the control of vascular tone.6

The cerebral circulation is supplied with a dense network of CGRP-like immunoreactive nerve fibers that originate in the trigeminal ganglia,7,8 the dorsal upper cervical cord,9 and in the internal carotid miniganglia.10 CGRP is a strong vasodilator of cerebral arteries both in vitro11 and in situ,12 inducing relaxation via non–endothelium-dependent and endothelium-dependent mechanisms with an associated activation of adenylate cyclase.13 It has been hypothesized that the cerebrovascular CGRP neuronal system operates to restore normal cerebrovascular tone after vasoconstriction occurring during a pathological event, such as would occur with migraine or after subarachnoid hemorrhage (SAH).12 Patients suffering an SAH have high jugular venous CGRP levels,14 and the cerebral vasculature is depleted of this peptide if death occurs in the acute stages following the hemorrhage.15 A depletion of this peptide may contribute to the onset of delayed cerebral ischemia after SAH.

In anesthetized rats an intravenous infusion of CGRP does not affect cerebral blood flow (CBF) or systemic blood pressure below a threshold dose of 120 ng/kg per minute.16 At 100 ng/kg per minute intravenous CGRP has been shown to reverse the decrease in CBF that occurs after extracranial carotid artery dissection in the rats.17

The aim of this study was to assess the effect on CBF and cerebral ischemia of 100 ng/kg per minute IV CGRP started 1 hour before middle cerebral artery (MCA) occlusion in the anesthetized rat. Our hypothesis was that exogenous CGRP would supplement the endogenous peptide, maximize cerebral vasodilatation, and reduce the extent of focal cerebral ischemia.

Results

Calcitonin gene–related peptide produces a significant improvement in ischemic cerebral blood flow (32±2 compared with 13±2 mL/100 g per minute in the controls; r=6.92, P<.0001) with a concomitant reduction in the volume of ischemic brain injury (102±22 compared with 234±19 mm³; r=4.47, P<.001).

Conclusions

These findings lend support for the potential use of this peptide in the prophylactic treatment of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

Key Words • cerebral ischemia, focal • neuropeptides • subarachnoid hemorrhage • rats

See Editorial Comment, p 2058
intra venous gallamine triethiodide (12 mg/kg) and ventilated via a tracheotomy. The left femoral artery was cannulated to monitor blood pressure and heart rate and to allow sampling for blood gas estimations. The left femoral vein was cannulated for the administration of CGRP (100 ng/kg per minute), or normal saline in the control groups, which was started 1 hour before and continued throughout 4 hours of left MCA occlusion.

MCA occlusion was achieved using an endovascular suture as described by Longa and his colleagues. A 3-0 monofila ment nylon suture was introduced into the left internal carotid artery via an arteriotomy in the isolated external carotid artery to an average depth of 22 mm. This suture lodged in the narrow proximal segment of the anterior cerebral artery, producing occlusion of the origin of the MCA.

CBF was measured using the hydrogen clearance technique, via two platinum electrodes (diameter, 0.125 mm) in each hemisphere placed to an intradural depth of 1 mm, through two burr holes sited over the lateral parietal skull at the bregma (anterior site) and 6 mm posterior to this (posterior site). Before CBF measurement the electrodes were allowed to stabilize for 1 hour and were polarized 400 mV positive relative to a silver/silver chloride reference electrode placed subcutaneously in the anterior abdominal wall. Hydrogen was introduced into the ventilator circuit through a parallel gas input as a 20% mixture with air and oxygen to achieve brain tissue saturation. The electrical currents produced clearance curves that were analyzed during the 45- to 105-second interval to estimate CBF at the four electrode sites. Repeated measurements of CBF were made once during each hour of the experiment.

Blood pressure, pulse rate, and body temperature were continuously monitored; blood gas analysis was performed half-hourly, and CBF estimations were calculated hourly. All animals remained normoglycemic, and ventilation parameters were altered appropriately to achieve blood gas tensions within normal limits.

Each rat that underwent 4 hours of MCA occlusion was then heparinized (2000 U/kg IV), and a midline thoracotomy was performed to gain access to the ascending aorta. The occlusive nylon suture was then removed from the internal carotid artery, and the animals were killed by exsanguination followed by perfusion-fixation with neutral formalin at 90 mm Hg. After 24 hours of immersion in formalin the brain was removed from the skull and cut into blocks to be processed through a series of formalin/alcohol/chloroform solutions and embedded in polyester wax. Coronal sections 7 µm thick were cut on a microtome, mounted on albumin-coated glass slides, and dried for 12 hours before staining with hematoxylin and eosin.

TABLE 1. Average Physiological Variables During the 4-Hour Period of Middle Cerebral Artery Occlusion

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control</th>
<th>CGRP</th>
<th>Statistical Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAP, mm Hg</td>
<td>100±2</td>
<td>102±2</td>
<td>t=3.52, P&lt;.005</td>
</tr>
<tr>
<td>HR, bpm</td>
<td>399±7</td>
<td>397±8</td>
<td></td>
</tr>
<tr>
<td>P02, kPa</td>
<td>20±1</td>
<td>21±1</td>
<td></td>
</tr>
<tr>
<td>PCO2, kPa</td>
<td>5.1±0.1</td>
<td>4.8±0.2</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>7.33±0.01</td>
<td>7.35±0.02</td>
<td></td>
</tr>
</tbody>
</table>

CGRP indicates calcitonin gene-related peptide; MAP, mean arterial pressure; HR, heart rate; and bpm, beats per minute. Data are expressed as mean±SEM.

Results

There were no significant differences in basic physiological parameters (mean arterial pressure, heart rate, arterial gas tensions, and blood sugar) between the treatment and control groups (Table 1).

After preparatory carotid dissection but before MCA occlusion, CGRP increased CBF in both hemispheres from 85±3 to 105±5 mL/100 g per minute (mean±SEM; t=3.524, P<.005), which accords with previous findings. After MCA occlusion, CBF fell by 82% in the ischemic hemisphere of the control rats, with blood flows below 25 mL/100 g per minute, which is the ischemic threshold for rat neurons. In the CGRP group MCA occlusion reduced CBF by only 60% in the ischemic hemisphere, with flows maintained above the critical 25 mL/100 g per minute threshold throughout the 4-hour ischemic period (Table 2 and Fig 1).

Intravenous CGRP reduced the volume of ischemic brain injury from 234±19 to 102±22 mm³ (mean±SEM; t=4.469, P<.001), a reduction of 57%. In the cortex the volume of ischemic neuronal injury decreased by 53% (191±13 to 89±19 mm³; t=4.461, P<.001) and in the...
basal ganglia by 70% (42±10 to 13±6 mm³; \( t=2.539, P<.05 \)) (Fig 2).

**Discussion**

Our results demonstrate that pretreatment with intravenous CGRP markedly reduces the fall in CBF in this model of focal cerebral ischemia and reduces the volume of ischemic neuronal injury by 57%. The extrapolation of results and conclusions from animal stroke models to the clinical setting is fraught with difficulty, but the model of focal cerebral ischemia we have used is one of the best compromises available for the following reasons.

The endovascular suture technique of MCA occlusion produces a reproducible volume of ischemic neuronal injury (234±64 mm³, mean±SD) and has a number of advantages over direct methods of occlusion. The nylon suture technique is minimally invasive, producing an occlusion at the origin of the MCA that can be confirmed by observing the change in a hydrogen clearance curve in progress at the time of occlusion, and it avoids the problems of a craniectomy, such as loss of cerebrospinal fluid and alteration of intracranial fluid dynamics.

The use of the hydrogen clearance technique to measure CBF has distinct advantages over other techniques in allowing the simultaneous determination of quantitative local CBF at multiple sites repeatedly during the same experiment. The spreading depression injury from electrode implantaation can lower CBF by 30% to 70% in acute experiments, but our use of small electrodes (0.125 mm in diameter) placed to an intradural depth of 1 mm minimizes this effect. The technique only provides CBF data from a small volume of tissue around the electrode and does not provide a complete picture of MCA blood flow; however, the standardization of electrode placement allows repeatable comparisons of CBF within groups of experiments. Our histological assessment of neuronal injury is based on changes identifiable by light microscopy after 4 hours of MCA occlusion, but it is possible that additional tissue is subjected to injury beyond this time.

The ischemic neurons are shrunken, angulated, and densely stained and are readily differentiated from healthy neurons, allowing the quantification of ischemic territory before the development of infarction. A major advantage of analyzing ischemic damage acutely is that key physiological variables, such as systemic arterial blood pressure and blood gas status, are monitored intensively right up to perfusion fixation, eliminating any secondary cerebral insults that may occur in recovery experiments. However, if permanent focal ischemia is extended for 24 hours, more of the ischemic penumbra may be recruited into the infarct, and CGRP may not reduce the ultimate infarct volume to the same extent.

It has been previously reported that exogenous intravenous CGRP reverses the fall in global CBF after carotid dissection, and the present results concur with these findings. The 10% fall in global CBF is presumably a result of global vasorestriction caused by activation of the cerebrovascular sympathetic system. Intravenous CGRP reverses this fall and, in the presence of an intact blood-brain barrier, must be achieving this effect through an endothelium-dependent process, perhaps linked to the release of nitric oxide.

In the ischemic MCA territory the cerebral vasculature will be dilated as a result of local hypoxia, hypercarbia, low flow, and the putative release of endogenous vasodilators such as CGRP. We hypothesized that the exogenous administration of CGRP would potentiate vasodilatation and improve the ischemic microenvironment. The CBF threshold for ischemic neuronal injury in rats is 25 ml/100 g per minute, and in the two sites measured in the ischemic hemisphere, pretreatment with CGRP maintained CBF above this level and reduced the volume of neuronal injury, supporting our hypothesis. Maximal dilatation of the origin of the MCA in the presence of relative MCA occlusion would improve blood flow, particularly at proximal sites, and could explain the differential benefit seen in the basal ganglia compared with the cortex. Alternatively, the basal ganglia may be more resistant to ischemic injury than cortex and derive greater benefit from the better maintained flow with CGRP.

Animal models of focal cerebral ischemia that achieve absolute occlusion of the MCA by ligation or diathermy produce a core of ischemia based on the caudate-putamen. The lack of an anastamotic supply to this region renders it severely compromised with an absolute proximal MCA occlusion, but in our model the volume of deep ischemic neuronal damage is reduced by...
70% (P<0.05) by the infusion of CGRP. Although we have no data on deep CBF, CGRP is presumably achieving an increased CBF in the proximal MCA, either by maximally dilating its origin or improving the anastomotic supply from anterior and posterior cerebral arteries.

In patient groups at high risk of cerebral ischemia, such as those suffering an SAH from an intracranial aneurysm or undergoing carotid endarterectomy, the potential benefit of this peptide is considerable. A recent clinical trial of intravenous CGRP in SAH involved giving the agent after the onset of delayed cerebral ischemia; although a trend to improvement occurred, the trial was too small to show a statistically significant improvement in outcome. Further research in the laboratory is needed to delineate the therapeutic window for this peptide, and current evidence warrants a clinical trial of sufficient size using prophylactic CGRP after SAH has occurred but before the development of delayed cerebral ischemia.

Acknowledgments

This study was funded by a grant from the Neurosciences Research Foundation (UK Charity Registration No. 288438). Technical assistance from Ron Howard, Fred Mitchell, and Chris Entwhistle (Atkinson Morley's Hospital, Medical Physics Department) is gratefully acknowledged in the establishment of the hydrogen clearance equipment.

References


28. European CGRP in SAH Study Group. Effect of calcitonin gene-related peptide (CGRP) on the most potent polypeptide vasodilators in cerebral arteries,1
Calcitonin gene-related peptide reduces brain injury in a rat model of focal cerebral ischemia.

J P Holland, S G Sydserff, W A Taylor and B A Bell

Stroke. 1994;25:2055-2058
doi: 10.1161/01.STR.25.10.2055

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/25/10/2055